Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
The effects on the fibrinolytic system after a single s.c. bolus injection (at 9 a.m.) of either 5000 IU conventional heparin or 5000 anti-Xa U of a fractionated low molecular weight heparin (Fragmin, KabiVitrum, Sweden) were investigated in 9 healthy volunteers. The effects were compared to those of an injection of normal saline in 6 volunteers. Samples for biochemical analyses were taken regularily during 6 hours after drug or placebo administration. In the coagulation system the following parameters were measured: Activated partial thromboplastin time (APTT), anti-Xa activity, thrombin time and fibrinogen. The fibrinolytic system was monitored by analysing: plasminogen, alpha 2-antiplasmin, fibrin(ogen) degradation products (FDP), euglobulin clot lysis time (ECLT), tissue plasminogen activator (t-PA) activity, t-PA antigen and plasminogen activator inhibitor (PAI) activity. Injection of the 2 drugs was followed by elevations in APTT and anti-Xa activity, and were more pronounced for Fragmin than heparin. The fibrinolytic system exhibited a diurnal variation with decreasing PAI activity and increasing t-PA activity during the day. Volunteers receiving normal saline (placebo) showed a similar pattern. The results were unrelated to heparin. It is concluded from this study that neither heparin nor Fragmin had any significant effect on the fibrinolytic parameters when measured after a single s.c. bolus injection since the observed variations were within the diurnal range.
Eriksson
E
E
Department of Surgery, Sahlgrenska sjukhuset, University of Göteborg, Sweden.
Wollter
I M
IM
Christenson
B
B
Stigendal
L
L
Risberg
B
B
D000328:Adult; D002940:Circadian Rhythm; D015951:Factor Xa; D005342:Fibrinolysis / Q000187:drug effects*; D006023:Glycoproteins / Q000097:blood; D006493:Heparin / Q000008:administration & dosage*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D015849:Plasminogen Inactivators; D015842:Serine Proteinase Inhibitors; D010959:Tissue Plasminogen Activator / Q000097:blood
D006023:Glycoproteins; D006495:Heparin, Low-Molecular-Weight; D015849:Plasminogen Inactivators; D015842:Serine Proteinase Inhibitors; D006493:Heparin; D015951:Factor Xa; D010959:Tissue Plasminogen Activator